Theratechnologies Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resistant HIV-1
MONTREAL, Oct. 26, 2021 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a…
Month: October 2021
Immunicum Appoints Lotta Ferm as Chief Financial Officer
Press Release 26 October 2021 Immunicum Appoints Lotta Ferm as Chief Financial Officer Immunicum AB…
Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz
Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +5% (cc¹, +6%…
Idorsia announces financial results for the third quarter 2021 – company progressing and launch preparations in key markets well underway
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 26, 2021Idorsia Ltd…
Bone Therapeutics Provides Third Quarter 2021 Business Update
REGULATED INFORMATION Recruitment ALLOB tibial fracture Phase IIb trial slower than anticipated due to pandemic…
Ventyx Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ENCINITAS, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX), a clinical-stage…
AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard
AnaptysBio to receive $250 million upfront cash payment from Sagard Healthcare Royalty Partners Sagard to…
Certara’s Simcyp™ COVID-19 Vaccine Model Wins R&D 100 Award
Biosimulation tool to conduct ‘what-if’ scenarios with virtual patients recognized in Software/Services category PRINCETON, N.J.,…
89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD’s The Liver Meeting 2021
Data from a new sub-analysis of the Phase 1b/2a study in NASH shows correlation between…
4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia
– First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary…
ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) — ADMA Biologics, Inc….
Revelation Biosciences Inc. Engages Destum Partners Inc. to Identify Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide)
-Anti-viral nasal drop REVTx-99 has potential to broadly prevent or treat respiratory infections including influenza,…
Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update
CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome…
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical…
Erasca Announces Presentation of Preclinical Data on ERAS-801, a CNS-Penetrant EGFR Inhibitor with Broad Activity against Oncogenic EGFR Alterations, at AACR Conference on Brain Cancer
ERAS-801’s CNS penetration: four times higher than approved EGFR inhibitorsComprehensive inhibition against oncogenic EGFR vIII…
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 4, 2021
SAN CARLOS, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a…
Gritstone Announces Presentations during Five Upcoming Investor Conferences and Events
EMERYVILLE, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage…
Todos Medical Announces Publication in Nature Neuroscience That Describes the Main Protease (3CL Protease) Causes Microvascular Brain Pathology
New York, NY, and Tel Aviv, ISRAEL, Oct. 25, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Todos…
INmune Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, November 3
Management to host conference call and webcast at 4:30 pm ET on that day Boca…
Panbela Schedules Conference Call on November 10, 2021, to Report 2021 Third Quarter Financial Results
MINNEAPOLIS , Oct. 25, 2021 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…